Share ownership Celyad Oncology SA

CYAD

BE0974260896

Biotechnology & Medical Research

Market Closed - Euronext Bruxelles Other stock markets 11:55:00 2026-01-16 am EST			5-day change	1st Jan Change
0.1750 ^EUR	+1.16%		-7.65%	+2.94%

25-09-30	Celyad Oncology to Sell Belgian Research Facility for EUR3 Million	MT
25-09-29	Celyad Oncology announces research facility divestiture	RE

Share class: Celyad Oncology SA

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	41,428,572	37,006,679 ( 89.33 %)	0	89.33 %

Major shareholders: Celyad Oncology SA

Name	Equities	%	Valuation
BNP Paribas Asset Management Belgium SA 0.0754 %	33,741	0.0754 %	6 737 €

Breakdown by shareholder type

Institutional	0.08%
Unknown	99.92%

Based on 1000 largest holdings

Geographical origin of shareholders

Belgium

0.08%

Based on 1000 largest holdings

Celyad Oncology SA is a biotechnology company focused on the discovery and development of innovative technologies chimeric antigen receptor (CAR) T-cell therapies. The company is focusing on opportunities to fully harness the true potential of its proprietary technology platforms and intellectual property and support the development of next-generation CAR T candidates in solid tumors and hematological malignancies.

Employees

Sector

Biotechnology & Medical Research

Calendar

Mar. 18 - Q4 2025 Earnings Release (Projected)

More about the company